Literature DB >> 12467217

Cellular and molecular pharmacology of oxaliplatin.

Eric Raymond1, Sandrine Faivre, Stephen Chaney, Jan Woynarowski, Esteban Cvitkovic.   

Abstract

Oxaliplatin, a diaminocyclohexane-containing platinum, has a spectrum of activity and mechanisms of action and resistance that appear to be different from those of other platinum-containing compounds, notably cisplatin. The first part of this review describes the differences between oxaliplatin and cisplatin in terms of their spectrum of activity and adduct formation and then goes on to discuss molecular and cellular experimental data that potentially explain them. Particular emphasis is placed on the differential role of DNA repair mechanisms. In addition, the anticancer effects of oxaliplatin are optimized when it is administered in combination with other anticancer agents, such as 5-fluorouracil, gemcitabine, cisplatin, or carboplatin; topoisomerase I inhibitors; and taxanes. In vitro and preclinical combination data that could optimize oxaliplatin-based chemotherapy are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467217

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  127 in total

1.  Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.

Authors:  John M Carethers
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

2.  Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.

Authors:  Hea-Kyoung Cho; Eun-Sook Lee; Jung-Won Lee; Jong-Kook Park; Jin-Hyoung Kang; Kyung-Shik Lee; Chang-Koo Shim; Suk-Jae Chung; Dae-Duk Kim; Hyo-Jeong Kuh
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-04       Impact factor: 4.553

Review 3.  Oxaliplatin: in operable colorectal cancer.

Authors:  Susan J Keam; Christopher J Dunn; David P Figgitt
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs.

Authors:  Thomas J Preston; Jeffrey T Henderson; Gordon P McCallum; Peter G Wells
Journal:  Mol Cancer Ther       Date:  2009-06-30       Impact factor: 6.261

Review 5.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.

Authors:  M Montopoli; E Ragazzi; G Froldi; L Caparrotta
Journal:  Cell Prolif       Date:  2009-02-18       Impact factor: 6.831

7.  Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Authors:  Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter
Journal:  Oncoimmunology       Date:  2018-02-16       Impact factor: 8.110

8.  X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage.

Authors:  Nicola Pontillo; Giarita Ferraro; John R Helliwell; Angela Amoresano; Antonello Merlino
Journal:  ACS Med Chem Lett       Date:  2017-02-28       Impact factor: 4.345

9.  A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.

Authors:  Sun Young Kim; Yong Sang Hong; Byung Chang Kim; Ji Won Park; Hyo Seong Choi; Seung-Yong Jeong; Dae Yong Kim; Chang Won Hong; Dae Kyung Sohn; Kyung Hae Jung
Journal:  Invest New Drugs       Date:  2008-09-25       Impact factor: 3.850

10.  Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.

Authors:  Carmen Plasencia; Albert Abad; Eva Martinez-Balibrea; Miquel Taron
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.